ClinicalTrials.gg
Status unknownNCT02665910Updated Apr 19, 2016

Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) Patients

A Phase 1 interventional study of SHR0302 and SHR0302 placebo comparator in Rheumatoid Arthritis, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-04-19.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2016), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd. — none open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
4th of 11
48 · median 30
Started
2016
with 1 other
Phase 1
8 of 11
none open now
Registered
2nd of 11
by date

Among the 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd., this one is the 4th largest by planned enrollment, is one of 2 that started in 2016, is one of 8 in phase 1, and was the 2nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd. is open now. The open studies under Arthritis, Rheumatoid, anywhere →

Where they have run

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd. as a file.
02

Study summary

Condition: Rheumatoid Arthritis Intervention: Drug: SHR0302; Drug: SHR0302 placebo comparator Phase: Phase 1 Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Randomized

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects who are 18\~70 years of age on the day of signing ,
  • Have a diagnosis of RA meeting the 1987 ACR/EULAR criteria of RA and ACR functional class I-III,
  • (BMI = weight/height squared (kg/m2)) within the range of 19 to 30,
  • Have agreed to not use any anti- rheumatic drug except for study drugs during the study period.

Exclusion criteria

Exclusion Criteria:

  • Current therapy with any disease modifying anti-rheumatic drug (DMARD), with the exception of Methotrexate (MTX), Leflunomide, sulfasalazine, antimalarials, gold preparations, penicillamine, which must have discontinued for a period of at least 7 t1/2s prior to dosing,
  • Previous RA treatment with DMARDs or drugs with strong effect in 3 months prior to dosing (12 months for rituximab or other B cell depleting agents),
  • Previous therapy with NSAIDs or oral in 2 weeks before dosing,
  • Any parenteral (intramuscular or intravenous injection) or intra-articular corticosteroids therapy in 4 weeks before dosing,
  • Previous treatment with interferons in 4 weeks before dosing.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    SHR0302

    Multiple ascending doses (2, 5, 10, 25 mg), oral tablets

    Drug: SHR0302

  • Placebo comparator
    SHR0302 placebo comparator

    Multiple ascending doses (2, 5, 10, 25 mg), oral tablets (matching corresponding study medication)

    Drug: SHR0302 placebo comparator

Interventions

  • Oral tablets (1 mg, 5 mg, 10 mg)

  • DrugSHR0302 placebo comparator

    Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)

06

What researchers measure

Primary outcomes

  1. Adverse events and the number of volunteers with adverse events as a measure of safety and tolerability.

    Tests will be performed to assess whether the study drug has any potentially adverse effect (laboratory tests on blood and urine for functioning of organs; cardiovascular testing, i.e. of heart and blood circulation). Also, participants will carefully be monitored by medical staff for vital signs, and asked to report any side effect experienced in the course of the study

    Time frame: up to 48 hrs postdose

Secondary outcomes

  1. The maximum plasma concentration (Cmax) of SHR0302

    Blood samples are taken on various timepoints to assess the pharmacokinetic parameters

    Time frame: At protocol-specified times up to 48 hrs postdose

  2. The area under the plasma concentration-time curve (AUC) of SHR0302

    Time frame: At protocol-specified times up to 48 hrs postdose

  3. t1/2 of SHR0302

    Time frame: At protocol-specified times up to 48 hrs postdose

Other outcomes

  1. Pharmacodynamics (PD) parameters of percent and actual change from baseline for a panel of JAK dependent biomarkers

    To characterize the effects of SHR0302 on mechanism of action-related biomarkers in the blood over time - pharmacodynamics (PD) - in RA.

    Time frame: At protocol-specified times up to 24 hrs postdose

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, 100032, China
    • Pei Hu, PhD · Contactpei.hu.pumc@gmail.com · 86-010-69158366
    • Pei Hu, PhD · Principal investigator
    • Xiaofeng Zeng, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2016 and a primary completion of Dec 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2016
First posted
Jan 28, 2016
Start
May 2016
Primary completionEst.
Dec 2016
Last update
Apr 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02665910
Responsible party
Sponsor
First posted
Jan 28, 2016
Start date
May 2016
Primary completion
Dec 2016 (estimated)
Last update
Apr 19, 2016

Study contacts

Chengyu Guan, MD
Contact
guanchengyu@hrs.com.cn
15705155015
Pei Hu, PhD
principal investigator · Peking Union Medical College Hospital
Xiaofeng Zeng, MD
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivarmacitinib

Start the discussion